NeoGenomics Q2 2026: NGS Revenue Surge Drives a 49% EPS Beat
As seen on the 24/7 Wall St. homepage on July 28, 2026.
NeoGenomics cleared the bar with adjusted EPS of $0.05, crushing consensus by 49%, as a 26% surge in next-generation sequencing revenue drove average test prices up 12% to $515 and pushed margins 260 basis points higher. Management raised full-year guidance on the strength of this higher-value mix shift.
Continue ReadingShow less
NeoGenomics reported adjusted earnings per share of $0.05 for Q2 2026, well ahead of the $0.034 consensus estimate — a beat of roughly 49%. Revenue came in at $201.7 million, topping expectations of $197.0 million by about 2%. The quarter's outperformance was powered by a 26% jump in next-generation sequencing revenue, which pulled the average price per test up 12% to $515 and expanded margins by 260 basis points.
The NGS growth story is central to what investors are watching at NeoGenomics. Higher-value genomic tests carry better economics than the company's legacy menu, and this quarter showed that mix shift is beginning to meaningfully show up in the financials. That 260-basis-point margin expansion, achieved alongside double-digit volume-driven pricing gains, is the kind of operating leverage that tends to get analysts revisiting their models.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Management responded to the quarter's momentum by raising full-year guidance. Looking back across recent quarters, results have been uneven — the company posted a loss of $0.20 per share in Q1 2025 against an estimated loss of $0.01 — making the current streak of profitable quarters, including $0.06 in Q4 2025 and now $0.05 in Q2 2026, a notable turn. Whether the NGS mix shift can sustain that trajectory into the back half of the year is the key question heading into Q3.
Mentioned: NEO